Recherches & Rapports

Boehringer Ingelheim stopped the Phase 1 study of its oral small‑molecule candidate BI 3031185 after a safety event, without revealing details. The trial began in early July in Fukuoka, Japan.

A myTomorrows survey of 100 US clinical trial site staff found 59% cite recruitment inefficiencies as cutting eligible patient enrollment, with many referrals deemed ineligible before screening.

Wegovy (semaglutide) is gaining attention for delivering weight loss that also supports cardiovascular health and muscle preservation, as shown by large trials and real‑world data.

Roche announced it will discontinue the Phase 2 trial of tominersen and the Phase 1 trial of RG6496, ending its Huntington’s disease program and disappointing patients.

Inofutics secured a support agreement for its IPS101A Parkinson’s gene therapy, now part of Korea’s 2026 national new drug development project, aiming to complete Phase 1 and obtain Phase 2 approval within two years.

The American Society of Clinical Oncology held ASCO Breakthrough 2026 in Singapore, highlighting abstracts on blood‑based multi‑cancer screening, HER2‑positive breast cancer therapies, PIK3CA‑mutated breast cancer precision treatment, early palliative care, and GLP‑1 agonist colon cancer prevention.

Korea's pharma and biotech firms focus on July events including R&D disclosures, FDA submissions, clinical data and Q2 earnings, with analysts watching a potential sector re‑evaluation.

Astellas Pharma's mirabegron study for overactive bladder in China is completed. The study evaluated efficacy and safety of mirabegron.